Ocumetics Extends Debenture Forbearance and Closes $1.02 Million LIFE Financing

Ocumetics Technology Corp ( (TSE:OTC) ) has issued an announcement.

Ocumetics Technology Corp. has secured a forbearance agreement with holders of up to $4 million in secured convertible debentures issued in 2024, under which lenders will refrain from enforcing repayment or realizing on security until June 19, 2027, despite the debentures’ earlier maturity. In exchange, the company issued more than 9.1 million bonus share purchase warrants and maintained conversion features on the principal and interest, providing near-term balance sheet relief while preserving potential equity upside for debentureholders.

Separately, Ocumetics reported the termination of its listed issuer financing exemption offering, having raised approximately $1.02 million through the sale of 1,706,383 units at $0.60 each, with attached warrants exercisable at $0.75 until late 2028. The combined measures bolster liquidity and extend debt flexibility as the company advances its ophthalmic technology programs, potentially stabilizing its capital structure during a key development phase for its intraocular lens platform.

The most recent analyst rating on (TSE:OTC) stock is a Hold with a C$0.53 price target. To see the full list of analyst forecasts on Ocumetics Technology Corp stock, see the TSE:OTC Stock Forecast page.

Spark’s Take on TSE:OTC Stock

According to Spark, TipRanks’ AI Analyst, TSE:OTC is a Neutral.

The score is primarily held down by very weak financial performance (no revenue, ongoing losses, negative equity, and persistent cash burn). Technicals also remain bearish with the stock trading below key moving averages and negative MACD, despite oversold readings. Positive corporate updates around clinical progress and financing provide some support but are not yet reflected in operating fundamentals.

To see Spark’s full report on TSE:OTC stock, click here.

More about Ocumetics Technology Corp

Ocumetics Technology Corp. is a Canadian research and product development company focused on advanced vision correction solutions in the ophthalmology sector. It is developing state-of-the-art intraocular lenses and other vision-enhancing technologies, including a first-in-human early feasibility study of an intraocular lens intended to eliminate the need for glasses or contact lenses by using the eye’s natural muscle activity to provide clear vision at all distances.

Average Trading Volume: 32,135

Technical Sentiment Signal: Sell

Current Market Cap: C$27.86M

See more data about OTC stock on TipRanks’ Stock Analysis page.